Navigation Links
Watson Names Mark Durand Chief Financial Officer
Date:11/16/2007

CORONA, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced the appointment of Mark W. Durand, 48, as Senior Vice President and Chief Financial Officer.

Mr. Durand brings to Watson more than 20 years of executive pharmaceutical experience in finance, operations, business development and marketing. As Senior Vice President and Chief Financial Officer for Watson, Mr. Durand will be responsible for all of the Company's financial operations and will play a principal role in Watson's corporate development activities. He will report directly to Paul Bisaro, Watson's President and Chief Executive Officer.

"We are excited to bring someone with Mark's experience to join the executive management team," said Paul Bisaro. "His extensive experience in both the generic and branded pharmaceutical industries and familiarity with our business model will complement the strength we have within our finance and corporate development groups as we continue to position Watson for future growth."

Mr. Durand joins Watson following his position as Chief Financial Officer and Senior Vice President Finance and Business Development for Teva Pharmaceuticals N.A., where he was responsible for all financial functions and business development activities related to Teva's North America operations, including licensing activities. He also played an integral role in the integration of Ivax Pharmaceuticals after it was acquired by Teva. Prior to his tenure at Teva, Mr. Durand held a number of positions of growing responsibility in the areas of finance, business development and marketing at Bristol-Myers Squibb. His financial roles there included Vice President US Pharmaceutical Group and Vice President Finance and Business Development for Bristol's Worldwide Consumer Medicines and Specialty Pharmaceuticals Division.

Mr. Durand received a Bachelor of Science degree in Zoology from Duke University, a Master of Science degree in Biological Sciences from Dartmouth College and a Master of Business Administration from the University of Chicago.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
6. Mediware Names Thomas K. Mann Chief Executive Officer
7. Cleveland-based Health Care Tech Company Within3 Names New CEO
8. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
9. Patient Safety Authority Board of Directors Names Infection Advisory Panel
10. Hooper Holmes Names Chris Behling President of Health & Wellness Division
11. MDMA Names New Director of Federal Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... 2016 , ... The American Society for Aesthetic Plastic Surgery ... AnzuMedical™ Knowledge Sharing and Collaboration Platform™ , today announced a joint initiative ... to launch in July 2016 and will be a combined effort between ASAPS, ...
(Date:4/28/2016)... ... 28, 2016 , ... A first-time look at workers’ compensation claims in Kentucky ... Workers Compensation Research Institute (WCRI) announced, and that costs per claim were stable ... 16th Edition , found that indemnity costs per claim and benefit delivery expenses per ...
(Date:4/28/2016)... ... 2016 , ... Metabolic Nutrition today announced the upcoming launch of ... Games Get Fit and Sports Expo in Orlando, Florida. Attended by pro ... April 29-30, was selected as the perfect event to introduce the highly anticipated GlycoLoad. ...
(Date:4/28/2016)... ... 28, 2016 , ... Denise McCormick Baich had written poetry dating back to her childhood, but ... like a tsunami and took on a more spiritual tone. The desire to put the ... more with it than just file it away. Friends would ask her how she wrote ...
(Date:4/28/2016)... Hollywood, CA (PRWEB) , ... April 28, 2016 , ... ... emergency dental care as soon as possible is essential when it comes to dental ... may make the difference between saving and losing a tooth. Toothaches, knocked-out teeth, chipped ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016  ValGenesis, Inc., the market leader ... today announced that a prominent world provider ... chronic kidney failure has selected ValGenesis Validation ... validation process. The global medical device manufacturer ... manage their validation processes electronically. Upon completion ...
(Date:4/27/2016)... April 27, 2016  Hologic, Inc. (Nasdaq: ... results for the fiscal second quarter ended March ... of $0.24 increased 41.2%, and non-GAAP diluted EPS ... increased 5.8% on a reported basis, and 6.3% ... "We posted another good quarter, highlighted by 14.6% ...
(Date:4/27/2016)... , April 27, 2016 ... Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor ... announced its sales for the first quarter ended March ... and the execution of its commercial strategy. ...
Breaking Medicine Technology: